These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 29032031)

  • 1. Discovery of novel anti-angiogenesis agents. Part 8: Diaryl thiourea bearing 1H-indazole-3-amine as multi-target RTKs inhibitors.
    Sun Y; Shan Y; Li C; Si R; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():373-385. PubMed ID: 29032031
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors.
    Zhang L; Shan Y; Li C; Sun Y; Su P; Wang J; Li L; Pan X; Zhang J
    Eur J Med Chem; 2017 Feb; 127():275-285. PubMed ID: 28068599
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of novel anti-angiogenesis agents. Part 7: Multitarget inhibitors of VEGFR-2, TIE-2 and EphB4.
    Li C; Shan Y; Sun Y; Si R; Liang L; Pan X; Wang B; Zhang J
    Eur J Med Chem; 2017 Dec; 141():506-518. PubMed ID: 29102175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol.
    Pan X; Liang L; Si R; Wang J; Zhang Q; Zhou H; Zhang L; Zhang J
    Eur J Med Chem; 2019 Feb; 163():1-9. PubMed ID: 30503935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of multi-target receptor tyrosine kinase inhibitors as novel anti-angiogenesis agents.
    Wang J; Zhang L; Pan X; Dai B; Sun Y; Li C; Zhang J
    Sci Rep; 2017 Mar; 7():45145. PubMed ID: 28332573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
    Pavana RK; Choudhary S; Bastian A; Ihnat MA; Bai R; Hamel E; Gangjee A
    Bioorg Med Chem; 2017 Jan; 25(2):545-556. PubMed ID: 27894589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation and dynamics simulation of indazole derivatives with antiangiogenic and antiproliferative anticancer activity.
    Elsayed NMY; Serya RAT; Tolba MF; Ahmed M; Barakat K; Abou El Ella DA; Abouzid KAM
    Bioorg Chem; 2019 Feb; 82():340-359. PubMed ID: 30428414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel anti-angiogenesis agents. Part 9: Multiplex inhibitors suppressing compensatory activations of RTKs.
    Shan Y; Si R; Wang J; Zhang Q; Zhou H; Song J; Zhang J; Chen Q
    Eur J Med Chem; 2019 Feb; 164():440-447. PubMed ID: 30616052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naphthalimides exhibit in vitro antiproliferative and antiangiogenic activities by inhibiting both topoisomerase II (topo II) and receptor tyrosine kinases (RTKs).
    Wang X; Chen Z; Tong L; Tan S; Zhou W; Peng T; Han K; Ding J; Xie H; Xu Y
    Eur J Med Chem; 2013 Jul; 65():477-86. PubMed ID: 23770449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases.
    Lee JS; Kang Y; Kim JT; Thapa D; Lee ES; Kim JA
    Eur J Pharmacol; 2012 Feb; 677(1-3):22-30. PubMed ID: 22200628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.
    Xu P; Chu J; Li Y; Wang Y; He Y; Qi C; Chang J
    Bioorg Med Chem; 2019 Oct; 27(20):114938. PubMed ID: 31488358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis and biological evaluation of novel 1
    Liu J; Wen Y; Gao L; Gao L; He F; Zhou J; Wang J; Dai R; Chen X; Kang D; Hu L
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):72-84. PubMed ID: 31682465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel 2-aminobenzimidazole-based compound Jzu 17 exhibits anti-angiogenesis effects by targeting VEGFR-2 signalling.
    Lien JC; Chung CL; Huang TF; Chang TC; Chen KC; Gao GY; Hsu MJ; Huang SW
    Br J Pharmacol; 2019 Oct; 176(20):4034-4049. PubMed ID: 31368127
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of carbamide derived pyrimidine-thioindole conjugates as potential VEGFR-2 inhibitors with anti-angiogenesis effect.
    Sana S; Reddy VG; Bhandari S; Reddy TS; Tokala R; Sakla AP; Bhargava SK; Shankaraiah N
    Eur J Med Chem; 2020 Aug; 200():112457. PubMed ID: 32422489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis and biological evaluation of substituted pyrrolo[2,3-d]pyrimidines as multiple receptor tyrosine kinase inhibitors and antiangiogenic agents.
    Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Warnke LA
    Bioorg Med Chem; 2008 May; 16(10):5514-28. PubMed ID: 18467105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Double-edged Swords: Diaryl pyrazoline thiazolidinediones synchronously targeting cancer epigenetics and angiogenesis.
    Upadhyay N; Tilekar K; Safuan S; Kumar AP; Schweipert M; Meyer-Almes FJ; Ramaa CS
    Bioorg Chem; 2021 Nov; 116():105350. PubMed ID: 34547645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel VEGFR-2 inhibitors. Part 5: Exploration of diverse hinge-binding fragments via core-refining approach.
    Shan Y; Gao H; Shao X; Wang J; Pan X; Zhang J
    Eur J Med Chem; 2015 Oct; 103():80-90. PubMed ID: 26342134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of 1H-indazole derivatives as novel ASK1 inhibitors.
    Hou S; Yang X; Yang Y; Tong Y; Chen Q; Wan B; Wei R; Lu T; Chen Y; Hu Q
    Eur J Med Chem; 2021 Aug; 220():113482. PubMed ID: 33906048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
    Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
    Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.